Complete Filing Data
PSYENCE BIOMEDICAL LTD. reported Cash And Cash Equivalents of $6.14 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean PSYENCE BIOMEDICAL LTD. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Profit Loss | $1.0M | -$51.2M | -$3.2M |
| General And Administrative Expense | $1.2M | $557.9K | $366.4K |
| Sales And Marketing Expense | $483.5K | $80.6K | $7.0K |
| Research And Development Expense | $342.2K | $954.6K | $1.6M |
| Ifrs Operating Income Loss | -$2.8M | -$3.2M | |
| Other Comprehensive Income Net Of Tax Exchange Differences On Translation | -$9.9K | $3.7K | -$89.8K |
| Comprehensive Income | $1.0M | -$51.0M | -$3.3M |
| Other Comprehensive Income | $192.0K | -$89.8K | |
| Comprehensive Income Loss | -$51.0M | -$3.3M | |
| Other Comprehensive Income Loss Net Of Tax Exchange Differences On Translation | $3.7K | -$89.8K | |
| Profit Loss Before Tax | -$3.7M | -$2.8M | -$3.2M |
| Revenue From Interest | $95.8K | $2.1K | $1.6K |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net Of Tax | -$9.9K | $195.7K | -$89.8K |
| Other Comprehensive Income Loss | $192.0K | ||
| Interest Expense | $9.3K | $52.9K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash And Cash Equivalents | $6.1M | $733.2K | $1.3M | $1.8M |
| Other Current Receivables | $137.3K | $41.7K | $149.4K | $39.5K |
| Liabilities | $594.4K | $12.1M | $1.8M | $131.6K |
| Equity And Liabilities | $7.3M | $1.1M | $1.6M | $1.8M |
| Assets | $7.3M | $1.1M | $1.6M | $1.8M |
| Current Restricted Cash And Cash Equivalents | $36.0K | $29.6K | $29.6K | $32.0K |
| Trade And Other Current Payables | $755.2K | $1.8M | $131.6K | |
| Current Assets | $6.6M | $1.1M | $1.6M | $1.8M |
| Cash Flows From Used In Operating Activities | -$3.7M | -$2.9M | -$1.6M | |
| Cash Flows From Used In Financing Activities | $9.2M | $2.4M | $1.2M | |
| Adjustments For Increase Decrease In Accounts Payable And Accrued Liabilities | -$360.9K | -$1.0M | $1.7M | |
| Adjustments For Decrease Increase In Other Operating Receivables | -$95.6K | $107.6K | -$109.9K | |
| Retained Earnings | -$56.4M | -$57.5M | -$6.3M | |
| Cash Flows From Used In Investing Activities | -$16.2K | -$5.7K | ||
| Current Warrant Liability | $200.1K | $901.6K | ||
| Purchase Of Property Plant And Equipment Classified As Investing Activities | $9.9K | $5.7K | ||
| Property Plant And Equipment | $11.1K | $5.5K | ||
| Ifrs Convertible Debt Current | $7.7M | |||
| Stock Issued During Period Value Issued For Debt Settlement | $718.5K | |||
| Fair Valuegainloss On Warrant Liability | -$694.5K | $306.3K | ||
| Cash Flows From Used In Decrease Increase In Restricted Cash And Cash Equivalents | -$6.4K | |||
| Current Accounts Payable And Accrued Liabilities | $394.3K | $755.2K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2024 |
|---|---|
| Cash And Cash Equivalents | |
| Other Current Receivables | |
| Liabilities | |
| Equity And Liabilities | |
| Assets | |
| Current Restricted Cash And Cash Equivalents | |
| Trade And Other Current Payables | |
| Current Assets | |
| Cash Flows From Used In Operating Activities | |
| Cash Flows From Used In Financing Activities | |
| Adjustments For Increase Decrease In Accounts Payable And Accrued Liabilities | |
| Adjustments For Decrease Increase In Other Operating Receivables | |
| Retained Earnings | |
| Cash Flows From Used In Investing Activities | |
| Current Warrant Liability | |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | |
| Property Plant And Equipment | |
| Ifrs Convertible Debt Current | |
| Stock Issued During Period Value Issued For Debt Settlement | |
| Fair Valuegainloss On Warrant Liability | $306.3K |
| Cash Flows From Used In Decrease Increase In Restricted Cash And Cash Equivalents | |
| Current Accounts Payable And Accrued Liabilities |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Increase Decrease In Cash And Cash Equivalents | $5.4M | -$601.1K | -$419.2K |
| Proceeds From Contributions Of Parent | $1.2M | ||
| Proceeds From Current Borrowings | $2.5M | ||
| Proceeds From Borrowings Classified As Financing Activities | $1.0M | $2.5M | |
| Proceeds From Issuing Shares | 1.7M |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Weighted Average Shares | 193.0K | 10.9K | 8.4K |
| Diluted Earnings Loss Per Share | $5.24 | $-4,674.25 | $-394.06 |
| Basic Earnings Loss Per Share | $5.24 | $-4,674.25 | $-394.06 |
| Adjusted Weighted Average Shares | 193.0K | 10.9K | 8.4K |
| Number Of Shares Outstanding | 13.4M | 0.00 | |
| Stock Issued During Period Shares Issued For Reverse Takeover Transaction | 150.0K |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Professional Fees Expense | $1.6M | $1.2M | $1.3M | |
| Current Prepayments | $322.1K | $77.1K | $5.4K | |
| Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss | -$7.3K | -$2.7K | $26.9K | |
| Adjustments For Decrease Increase In Prepaid Expenses | $70.3K | -$245.1K | -$71.7K | |
| Adjustments For Unrealised Foreign Exchange Losses Gains | -$9.9K | $3.7K | -$84.5K | |
| Issued Capital | $61.8M | $46.1M | $5.9M | |
| Adjustments For Sharebased Payments | $317.9K | $221.3K | ||
| Other Reserves | $351.2K | $361.1K | $165.4K | |
| Finance Income | -$2.1K | |||
| Ifrs Fair Value Adjustment Of Warrants | -$694.5K | $306.3K | ||
| Depreciation Expense | $4.3K | $240.00 | ||
| Fair Value Adjustment On Promissory Note | -$705.6K | $108.3K | ||
| Fair Value Adjustment On Convertible Note | -$3.4M | $5.2M | ||
| Finance Costs | $52.9K | |||
| Adjustments For Depreciation Expense | $4.3K | $240.00 | ||
| Fair Value Adjustments On Promissory Note | -$705.6K | $300.3K | ||
| Increase Decrease Through Other Contributions By Owners | $1.4M | |||
| Other Income | $879.3K | |||
| Transaction Expense | $2.5M | |||
| Listing Expense | $41.5M | |||
| Adjustments For Transaction Expenses | $2.1M | |||
| Adjustments For Listing Expense | $41.5M | |||
| Fair Value Loss On Warrant Exchange | $185.1K | |||
| Stock Issued During Period Value Issuance Of Shares To Third Party Advisors | 241.4K | 2.1M | ||
| Repayments Of Borrowings Classified As Financing Activities | $150.0K | |||
| Current Prepaid Expenses | $251.8K | $322.1K | ||
| Warrant Reserve | $1.1M |
Most recent annual filing with the SEC: June 25, 2025
Data sourced from SEC EDGAR public filings as of August 7, 2026.